Fresh Equities



ACTINOGEN MEDICAL LIMITED has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.


2. View Terms

View the full term sheet for the capital raise.


3. Bid for Allocation

Submit and track your bid online.

Capital Raise History


Company Overview

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.


Listed Company

GICS Sub-industry


Head Office

Suite 901a, Level 9/109 Pitt St, Sydney NSW 2000, Australia

Health Care
Biotech & Health

Price Chart

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.




All Time
  • Appendix 4D & Half-Year Financial Statements on 20 February 2020

    Periodic Reports

  • Appendix 3Y-Dr Bill Ketelbey on 31 January 2020

    Shareholder Details

    ASIC Form 484 on 31 January 2020

    Issued Capital

    Final share buy-back notice - Appendix 3F on 31 January 2020

    Issued Capital

  • December 2019 Quarterly Update on 27 January 2020

    Commitments test entity quarterly reports

  • Actinogen at SACHS Forum and JP Morgan week on 7 January 2020

    Periodic Reports

    Review of 2019 and outlook on 17 December 2019

    Progress Report

    Share Cancellation - Employee Share Plan on 13 December 2019

    Issued Capital

    Managing Director share loan repayment on 26 November 2019

    Shareholder Details

    Results of Annual General Meeting on 25 November 2019

    Notice Of Meeting

    Load More


  • [PRESENTATION] Managing Director's AGM Presentation

    Posted at 28 November 2018.

  • [PRESENTATION] Actinogen updated investor presentation

    Posted at 26 November 2018.